RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication
Artículo científico (JournalArticle)
Primary human hepatocyte-laden scaffolds for the treatment of acute liver failure
[EN] Cell-based liver therapies based on retrieving and steadying failed metabolic function(s) for acute and chronic diseases could be a valuable substitute for liver transplants, even though they are limited by the low engraftment capability and reduced functional quality of primary human hepatocytes (PHH). In this paper we propose the use of gelatin-hyaluronic acid (Gel-HA) scaffolds seeded with PHH for the treatment of liver failure. We first optimized the composition using Gel-HA hydrogels, looking for the mechanical properties closer to the human liver and determining HepG2 cells functionality. Gel-HA scaffolds with interconnected porosity (pore size 102 ¿m) were prepared and used for PHH culture and evaluation of key hepatic functions. PHH cultured in Gel-HA scaffolds exhibited increased albumin and urea secretion and metabolic capacity (CYP and UGT activity levels) compared to standard monolayer cultures. The transplant of the scaffold containing PHH led to an improvement in liver function (transaminase levels, necrosis) and ameliorated damage in a mouse model of acetaminophen (APAP)-induced liver failure. The study provided a mechanistic understanding of APAP-induced liver injury and the impact of transplantation by analyzing cytokine production and oxidative stress induction to find suitable biomarkers of cell therapy effectiveness., This work has been supported by the Institute of Health Carlos III (Plan Estatal de I+D+i 2013-2016) and co-financed by the European Regional Development Fund "A way to achieve Europe" (FEDER) through grants PI18/00993, PI21/00223 and CP16/00097; by the Spanish Ministry of Science and Innovation MCIN/AEI/10.13039/501100011033 through the PID2019-106000RB-C21 and PID2019-106000RB-C22 Grants and by the Generalitat Valenciana (PROMETEO/2019/060) . L.T. was supported by ISCIII CP16/00097 and MV21/00044, E.V.B through grant FI22/00082 (ISCIII) . M.S-S was supported by an EPSRC Programme Grant (EP/P001114/1).
Project:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-106000RB-C22
,
Agencia Estatal de Investigación PID2019-106000RB-C21
,
Engineering and Physical Sciences Research Council EP/P001114/1
,
Reino Unido PROMETEO/2019/060
,
Generalitat Valenciana PI21/00223
,
Instituto de Salud Carlos III MV21/00044
,
Instituto de Salud Carlos III PI18/00993
,
Instituto de Salud Carlos III CP16/00097
,
Instituto de Salud Carlos III FI22/00082